The combination of CTLA-4 and PD-(L)1 inhibitors is approved for patients with metastatic melanoma, renal cell carcinoma, and subtypes of metastatic colorectal carcinoma [60], and a trial to evaluate the combination of nivolumab and ipilimumab in patients with thymic carcinoma and B3 thymoma is currently under way (NCT03134118) [61]. This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.